down arrow

Vivos Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US92859E2072
USD
2.15
0.1 (4.88%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Ekso Bionics Holdings, Inc.
NeuroMetrix, Inc.
Sharps Technology, Inc.
Vivos Therapeutics, Inc.
Seastar Medical Holding Corp.
BioRestorative Therapies, Inc.
Creative Medical Technology Holdings, Inc.
ENDRA Life Sciences, Inc.
Aethlon Medical, Inc.
Navidea Biopharmaceuticals, Inc.
Nemaura Medical, Inc.
Why is Vivos Therapeutics, Inc. ?
1
Poor Management Efficiency with a low ROE of 0%
  • The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Operating profit has grown by an annual rate -4.45% of over the last 5 years
3
Negative results in Jun 25
  • OPERATING PROFIT(Q) Lowest at USD -4.56 MM
  • PRE-TAX PROFIT(Q) Lowest at USD -5.01 MM
  • NET PROFIT(Q) Lowest at USD -5.01 MM
4
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -34.91%, its profits have risen by 30.8%
5
Underperformed the market in the last 1 year
  • Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -34.91% returns
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Vivos Therapeutics, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Vivos Therapeutics, Inc.
-39.94%
-0.11
95.48%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-0.26%
EBIT Growth (5y)
-4.45%
EBIT to Interest (avg)
-16.84
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
5.88
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
14.97%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.98
EV to EBIT
-1.00
EV to EBITDA
-1.05
EV to Capital Employed
4.45
EV to Sales
0.77
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-446.49%
ROE (Latest)
-254.98%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
NET PROFIT(HY)

Higher at USD -8.88 MM

-19What is not working for the Company
OPERATING PROFIT(Q)

Lowest at USD -4.56 MM

PRE-TAX PROFIT(Q)

Lowest at USD -5.01 MM

NET PROFIT(Q)

Lowest at USD -5.01 MM

RAW MATERIAL COST(Y)

Grown by 23.99% (YoY

DEBT-EQUITY RATIO (HY)

Highest at 156.64 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 14.2 times

Here's what is not working for Vivos Therapeutics, Inc.
Pre-Tax Profit
At USD -5.01 MM has Fallen at -78.45%
over average net sales of the previous four periods of USD -2.81 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
At USD -5.01 MM has Fallen at -78.45%
over average net sales of the previous four periods of USD -2.81 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Profit
Lowest at USD -4.56 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Operating Profit trend is quite negative

Operating Profit (USD MM)

Pre-Tax Profit
Lowest at USD -5.01 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
Lowest at USD -5.01 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Debt-Equity Ratio
Highest at 156.64 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio
Lowest at 14.2 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost
Grown by 23.99% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."